Skip to main content

VHCP Management II, LLC

13F filer · CIK 0001602263
Last filed Feb 13, 2020
Inactive · not filing 13F
13F portfolio value$379MU.S. long equity reported on 13F
Positions187 new · 8 closed
Net flow last quarter-$46.6MBuys minus sells
Top 10 positions weight90.8%Concentration

Holdings

13F · last 4 quarters free
Scroll for earlier quarters
CompanyValue% of portfolio% of companyPOSITION CHANGE qoq %First reported
Q4 2019Reported Feb 13, 202018 positions
TXG10x Genomics, Inc.$136M35.91%1.86%Not reportedQ3 2019
AXSMAxsome Therapeutics, Inc.$81.2M21.42%2.13%-12.0%Q1 2019
CNSTConstar International Inc$70.7M18.64%Not reported+106.5%Q3 2018
BHVNBiohaven Ltd.$25.2M6.64%Not reported-35.1%Q2 2017
KALVKalVista Pharmaceuticals, Inc.$6.52M1.72%2.05%-2.8%Q4 2016
OBSVObseva SA$6.01M1.58%3.24%-30.1%Q2 2017
MRSNMersana Therapeutics, Inc.$5.29M1.39%2.03%NewQ4 2019
SPROSpero Therapeutics, Inc.$4.56M1.20%2.47%Not reportedQ4 2017
RLMDRelmada Therapeutics, Inc.$4.48M1.18%0.79%NewQ4 2019
ADVMAdverum Biotechnologies, Inc.$4.42M1.16%0.57%Not reportedQ2 2016
MRNSMarinus Pharmaceuticals, Inc.$3.21M0.85%6.88%Not reportedQ2 2018
FTSVForty Seven, Inc.$3.06M0.81%0.16%NewQ4 2019
MISTMilestone Pharmaceuticals Inc.$2.38M0.63%0.61%Not reportedQ2 2019
NXTCNextCure, Inc.$2.04M0.54%0.13%NewQ4 2019
MYOVMyovant Sciences Ltd.$1.19M0.31%0.09%NewQ4 2019
ETNB89bio, Inc.$1.08M0.29%0.30%NewQ4 2019
BLPHBellerophon Therapeutics, Inc.$230K0.06%14.39%-84.1%Q3 2017
PTGXProtagonist Therapeutics, Inc$227K0.06%0.12%-92.5%Q4 2018
Q3 2019Reported Nov 13, 201919 positions
TXG10x Genomics, Inc.$90M34.31%1.86%NewQ3 2019
BHVNBiohaven Ltd.$29.7M11.33%Not reported-26.0%Q2 2017
ASNDAscendis Pharma A/S$22.6M8.61%0.56%-53.5%Q4 2015
OBSVObseva SA$18.8M7.15%4.95%Not reportedQ2 2017
AXSMAxsome Therapeutics, Inc.$18.1M6.89%2.59%Not reportedQ1 2019
RARXRa Pharmaceuticals, Inc.$16M6.10%1.44%Not reportedQ4 2016
BCRXBiocryst Pharmaceuticals Inc$8.24M3.14%2.60%Not reportedQ1 2016
PTGXProtagonist Therapeutics, Inc$5.13M1.95%1.57%Not reportedQ4 2018
SPROSpero Therapeutics, Inc.$5.03M1.91%2.54%Not reportedQ4 2017
CNSTConstar International Inc$4.69M1.79%Not reportedNot reportedQ3 2018
KNSAKiniksa Pharmaceuticals International, plc$4.6M1.75%Not reported-11.3%Q2 2018
LJPCLa Jolla Pharmaceutical Co$4.56M1.74%1.91%Not reportedQ1 2019
KALVKalVista Pharmaceuticals, Inc.$4.37M1.67%2.12%Not reportedQ4 2016
TCDATricida, Inc.$3.67M1.40%0.24%-72.3%Q2 2018
MISTMilestone Pharmaceuticals Inc.$2.77M1.06%0.61%Not reportedQ2 2019
MRNSMarinus Pharmaceuticals, Inc.$2.29M0.87%2.83%+99.9%Q2 2018
BLPHBellerophon Therapeutics, Inc.$2M0.76%6.02%Not reportedQ3 2017
RDUSRadius Recycling, Inc.$352K0.13%Not reportedNewQ3 2019
PRVLPrevail Therapeutics Inc.$32K0.01%0.01%NewQ3 2019
Q2 2019Reported Aug 13, 201919 positions
ASNDAscendis Pharma A/S$58.1M18.30%1.20%Not reportedQ4 2015
BHVNBiohaven Ltd.$42.2M13.29%Not reported-15.4%Q2 2017
OBSVObseva SA$25.5M8.03%4.95%Not reportedQ2 2017
AXSMAxsome Therapeutics, Inc.$23M7.25%2.60%+56.1%Q1 2019
RARXRa Pharmaceuticals, Inc.$20.4M6.42%1.60%+7.1%Q4 2016
ZGNXZogenix, Inc.$17.3M5.45%0.85%Not reportedQ3 2017
TCDATricida, Inc.$16.9M5.33%0.87%-55.5%Q2 2018
BCRXBiocryst Pharmaceuticals Inc$10.9M3.43%2.60%-11.5%Q1 2016
CNSTConstar International Inc$8.92M2.81%Not reportedNot reportedQ3 2018
KALVKalVista Pharmaceuticals, Inc.$8.35M2.63%2.18%-34.3%Q4 2016
KNSAKiniksa Pharmaceuticals International, plc$8.25M2.60%Not reported-4.7%Q2 2018
SPROSpero Therapeutics, Inc.$5.46M1.72%2.54%Not reportedQ4 2017
PTGXProtagonist Therapeutics, Inc$5.17M1.63%1.71%+57.3%Q4 2018
LJPCLa Jolla Pharmaceutical Co$4.79M1.51%1.91%+39.5%Q1 2019
MISTMilestone Pharmaceuticals Inc.$4.03M1.27%0.61%NewQ2 2019
MRNSMarinus Pharmaceuticals, Inc.$3.09M0.97%1.42%Not reportedQ2 2018
BLPHBellerophon Therapeutics, Inc.$2.49M0.79%6.02%Not reportedQ3 2017
KDMNKadmon Holdings, Inc.$514K0.16%0.19%-69.6%Q2 2018
GEMPMetaVia Inc.$382K0.12%Not reported-8.2%Q3 2018
Q1 2019Reported May 14, 201918 positions
ASNDAscendis Pharma A/S$59.3M17.37%1.20%Not reportedQ4 2015
BHVNBiohaven Ltd.$58.6M17.14%Not reportedNot reportedQ2 2017
TCDATricida, Inc.$37.2M10.88%2.27%0.0%Q2 2018
OBSVObseva SA$28.8M8.43%4.95%Not reportedQ2 2017
BCRXBiocryst Pharmaceuticals Inc$26.4M7.74%2.95%Not reportedQ1 2016
ZGNXZogenix, Inc.$19.9M5.83%0.85%Not reportedQ3 2017
KALVKalVista Pharmaceuticals, Inc.$16.4M4.80%3.33%-24.5%Q4 2016
RARXRa Pharmaceuticals, Inc.$14.2M4.15%1.50%Not reportedQ4 2016
KNSAKiniksa Pharmaceuticals International, plc$11.5M3.38%Not reportedNot reportedQ2 2018
CNSTConstar International Inc$9.85M2.88%Not reportedNot reportedQ3 2018
AXSMAxsome Therapeutics, Inc.$8.14M2.38%1.72%NewQ1 2019
SPROSpero Therapeutics, Inc.$6.07M1.78%2.73%Not reportedQ4 2017
PTGXProtagonist Therapeutics, Inc$3.41M1.00%1.16%+8.5%Q4 2018
MRNSMarinus Pharmaceuticals, Inc.$3.11M0.91%1.42%Not reportedQ2 2018
BLPHBellerophon Therapeutics, Inc.$2.71M0.79%6.02%Not reportedQ3 2017
LJPCLa Jolla Pharmaceutical Co$2.39M0.70%1.37%NewQ1 2019
KDMNKadmon Holdings, Inc.$2.17M0.63%0.65%-41.9%Q2 2018
GEMPMetaVia Inc.$591K0.17%Not reportedNot reportedQ3 2018
Premium opens every quarter this fund has filed

Not investment advice. We make every effort to keep the information on SpoorBase accurate, but errors may occur. SpoorBase does not guarantee the accuracy or completeness of any data, and any use of the information is at the user’s sole responsibility. Valuation multiples are calculated by SpoorBase and may contain errors. See Disclosures. © 2026 SpoorBase. All rights reserved.